HTA211 Are Surrogate Endpoints a Way Forward in Non-Small Cell Lung Cancer (NSCLC)? A Comparison of HTA Outcomes Across Germany, France, and the UK
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1669
https://www.valueinhealthjournal.com/article/S1098-3015(22)03874-8/fulltext
Title :
HTA211 Are Surrogate Endpoints a Way Forward in Non-Small Cell Lung Cancer (NSCLC)? A Comparison of HTA Outcomes Across Germany, France, and the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03874-8&doi=10.1016/j.jval.2022.09.1669
First page :
Section Title :
Open access? :
No
Section Order :
11223